| Identification | Back Directory | [Name]
3-(3-Hydroxy-1-oxo-2-phenylpropoxy)-8-methyl-8-(1-methylethyl)-8-azoniabicyclo(3.2.1)octane bromide monohydrate | [CAS]
66985-17-9 | [Synonyms]
Unii-J697uz2A9j
pratropium Bromide
IPRATROPIUM BROMIDE
Ipratropium Bromider
Ipratropium bromide CRS
Ipratropium Bromide (100 mg)
Ipratropium bromide 1-hydrate
IPRATROPIUM BROMIDE MONOHYDRATE
IpratropiumBromideMonohydrate>
8-methyl-8-propan-2-yl-8-azoniabicyclo[3.2.1]octan-3-yl
3-(3-Hydroxy-1-oxo-2-phenylpropoxy)-8-methyl-8-(1-methylethyl)-8-azoniabicyclo(3.2.1)octane bromide monohydrate | [EINECS(EC#)]
244-873-8 | [Molecular Formula]
C20H30NO3.Br.H2O | [MDL Number]
MFCD00792907 | [MOL File]
66985-17-9.mol | [Molecular Weight]
430.38 |
| Chemical Properties | Back Directory | [Appearance]
White or almost white, crystalline powder. | [Melting point ]
231 °C | [storage temp. ]
2-8°C | [solubility ]
H2O: soluble10mg/mL | [form ]
powder | [color ]
white | [Stability:]
Hygroscopic | [InChIKey]
KEWHKYJURDBRMN-XSAPEOHZNA-M | [SMILES]
C([N+]1([C@@H]2C[C@@H](OC(=O)C(C3C=CC=CC=3)CO)C[C@H]1CC2)C)(C)C.[Br-].O |&1:2,4,18,r| |
| Hazard Information | Back Directory | [Chemical Properties]
White or almost white, crystalline powder. | [Uses]
antihypertensive | [Definition]
ChEBI: The monohydrate form of ipratropium bromide. An anticholinergic drug, ipratropium bromide blocks the muscarinic cholinergic receptors in the smooth muscles of the bronchi in the lungs. This opens the bronchi, so providing relief in chronic obstructive pulm
nary disease and acute asthma. | [Brand name]
Atrovent (Boehringer Ingelheim). | [Description]
Ipratropium bromide is a quaternary ammonium congener of atropine and is an anticholinergic compound approved for use as a bronchodilator. Anticholinergic agents produce bronchodilatation by antagonizing the activity of acetylcholine at the level of its receptor, particularly those found on airway smooth muscle in the large, central airways. The onset of action of ipratropium is relatively slow (20 minutes), and the peak effect occurs at 60 minutes.1 Ipratropium, unlike atropine, is poorly absorbed across mucous membranes and has little toxicity at the usual doses.
| [Biochem/physiol Actions]
Ipratropium bromide monohydrate is a nonselective muscarinic acetylcholine receptor antagonist and a bronchodilator. In nebulized form, it is used for treating asthma and obstructive pulmonary diseases. It acts as a β2 adrenoreceptor agonist. Ipratropium bromide monohydrate is an anticholinergic agent and competes with acetylcholine. It promotes bronchodilation by stimulating sympathetic pathways. | [Clinical Use]
Anticholinergic bronchodilator:
Reversible airways obstruction, particularly in
COPD | [Side effects]
Previous severe allergic reaction symptoms upon using ipratropium or atropine and its other derivatives, such as angioedema, urticaria, severe shortness of breath, oropharyngeal edema, and ultimately anaphylaxis is a contraindication to ipratropium use.
Ipratropium aerosols can cause bronchospasms (paradoxical), which usually happens upon the initial use of this medication | [Drug interactions]
Potentially hazardous interactions with other drugs
None known | [Metabolism]
After inhalation, around 10-30% of a dose is deposited
in the lungs where it exerts its therapeutic effect. Only
a small amount of ipratropium reaches the systemic
circulation. The majority of a dose is swallowed but
is poorly absorbed from the gastrointestinal tract.
Ipratropium and its metabolites are eliminated in the
urine and faeces. |
|
|